Gilead Sciences News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

19.10.23	Gilead Sciences Presents Three-year Outcomes From BICSTaR Study With Biktarvy (RTTNews)
18.10.23	Gilead Launches New Study To Evaluate Lenacapavir In HIV Prevention As Part Of PURPOSE Program (RTTNews)
17.10.23	Gilead Partners With Assembly Biosciences To Accelerate Development Of Antiviral Therapeutics (RTTNews)
19.09.23	Gilead Sciences: CHMP Supports Veklury In Treatment Of COVID-19 In People With Hepatic Impairment (RTTNews)
18.09.23	Gilead's Kite Reports Positive Trial Results Of T-cell Therapy Yescarta In R/R Large B-cell Lymphoma (RTTNews)
10.09.23	Gilead : Phase 2 Study Of Trodelvy Combination Shows Promising Clinical Activity In Lung Cancer (RTTNews)
24.08.23	Gilead's Veklury Gets FDA Approval For COVID-19 In Mild To Severe Hepatic Impairment (RTTNews)
21.08.23	Gilead: FDA Places Partial Clinical Hold On Initiation Of New Patients In Magrolimab Studies (RTTNews)
15.08.23	Gilead, Tentarix Establish Multi-year Collaborations To Discover Protein Therapeutics (RTTNews)
03.08.23	Gilead Sciences Inc. Q2 Profit Decreases, misses estimates (RTTNews)
24.07.23	Cognizant Renews Partnership With Gilead Valued $800 Mln, For 5 Years (RTTNews)
24.07.23	Cognizant and Gilead Extend Partnership with Five-Year Service Agreement Estimated at $800 Million (PR Newswire)
14.07.23	FDA Approves Gilead's Veklury For COVID-19 Treatment In Patients With Severe Renal Impairment (RTTNews)
23.06.23	Gilead Sciences Gets CHMP Positive Opinion For Trodelvy In Metastatic Breast Cancer (RTTNews)
23.06.23	Gilead's Hepcludex Shows Sustained Efficacy, Safety In People With Chronic HDV At Week 96 (RTTNews)
26.05.23	Gilead : CHMP Grants Positive Opinion For Use Of Veklury In COVID-19 Patients With Renal Impairment (RTTNews)
04.05.23	CHMP Recommends Full Marketing Authorization For Gilead's Hepcludex To Treat Hepatitis Delta Virus (RTTNews)
28.04.23	Gilead Q1 Profit Misses View, But Revenues Top; Cuts FY EPS Outlook (RTTNews)
27.03.23	Everest Medicines Obtains Full Upfront Payment From Gilead For Trodelvy-Related Deal (RTTNews)
21.03.23	Kite Reports Primary Overall Survival Analysis Results Of Phase 3 ZUMA-7 Study (RTTNews)
20.03.23	Gilead Exercises Option To License Nurix's Protein Degrader Molecule NX-0479 (RTTNews)
17.02.23	Gilead : Phase 2 Data Show Benefit Of Trodelvy Across Multiple Types Of Metastatic Urothelial Cancer (RTTNews)
09.02.23	Kite's Tecartus CAR T-Cell Therapy Shows Sustained Benefit In 3-year Follow-up Of ZUMA-3 Trial (RTTNews)
04.02.23	Gilead Sciences : FDA Approves Trodelvy In Pre-treated HR+/HER2- Metastatic Breast Cancer (RTTNews)
02.02.23	Gilead Sciences Inc. Q4 Profit Increases, beats estimates (RTTNews)
29.01.23	Biotech Stocks Facing FDA Decision In February 2023 (RTTNews)
03.01.23	Gilead To Collaborate With EVOQ To Expand Autoimmune Pipeline (RTTNews)
27.12.22	Gilead To Acquire Remaining Rights To Immunotherapy GS-1811 From Jounce Therapeutics (RTTNews)
23.12.22	Kite Pharma : Yescarta Approved In Japan For Initial Treatment Relapsed Large B-Cell Lymphoma (RTTNews)
23.12.22	FDA Approves Gilead Sciences' HIV Drug For Adults With Limited Treatment Options (RTTNews)
20.12.22	Kite To Acquire Tmunity - Quick Facts (RTTNews)
09.12.22	Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma (PR Newswire)
09.12.22	ImmunoGen, Gilead To Evaluate Pivekimab With Magrolimab In R/R CD123-positive Acute Myeloid Leukemia (RTTNews)
08.12.22	Daiichi Sankyo To Transfer Yescarta Marketing Authorization In Japan To Gilead Sciences (RTTNews)
29.11.22	Gilead Granted Expanded Marketing Authorization For Biktarvy In The European Union (RTTNews)
28.11.22	Gilead, Arcus Announce Positive Update On Joint TIGIT Program In ARC-7 Study (RTTNews)
28.11.22	Biotech Stocks Facing FDA Decision In December 2022 (RTTNews)
10.11.22	Form 4 882095 (RSS)
02.11.22	Form 10-Q 882095 (RSS)
28.10.22	Gilead Sciences Inc. Q3 Profit Decreases, but beats estimates (RTTNews)
27.10.22	Form 8-K 882095 (RSS)
24.10.22	Gilead : Data Reinforce Use Of Biktarvy For HIV Treatment With Range Of Comorbidities (RTTNews)
17.10.22	Gilead, MacroGenics In Deal To Develop Bispecific Antibodies (RTTNews)
11.10.22	Gilead Sciences: FDA Accepts For Priority Review SBLA For Trodelvy - Quick Facts (RTTNews)
03.10.22	Gilead Company Kite Says FDA Oks RVV Manufacturing Facility In California For Commercial Production (RTTNews)
16.09.22	Gilead: Kite's CAR T-cell Therapy Yescarta Gets Positive Opinion From CHMP In EU (RTTNews)
16.09.22	Gilead Sciences Says CHMP Adopts Positive Opinion To Extend Indication Of Veklury (RTTNews)
16.09.22	Gilead Sciences : WHO Expands Recommendation For Veklury To Patients With Severe COVID-19 (RTTNews)
22.08.22	Gilead's Twice-yearly HIV Drug Sunlenca Gets European Commission Approval (RTTNews)
16.08.22	Gilead Sciences To Buy Remaining Worldwide Rights Of Trodelvy (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

20.12.24		Freundlicher Handel in New York: Dow Jones beendet die Sitzung weit in der Gewinnzone
20.12.24		Handel in New York: Am Freitagnachmittag Gewinne im Dow Jones
20.12.24		Dow Jones aktuell: Dow Jones notiert am Mittag im Plus
20.12.24		Schwacher Handel: SMI schliesst mit Verlusten
20.12.24		SPI-Handel aktuell: SPI zum Handelsende leichter
20.12.24		Handel in Europa: STOXX 50 schliesst im Minus

20.12.24

Freundlicher Handel in New York: Dow Jones beendet die Sitzung weit in der Gewinnzone

20.12.24

Handel in New York: Am Freitagnachmittag Gewinne im Dow Jones

20.12.24

Dow Jones aktuell: Dow Jones notiert am Mittag im Plus

20.12.24

Schwacher Handel: SMI schliesst mit Verlusten

20.12.24

SPI-Handel aktuell: SPI zum Handelsende leichter

20.12.24

Handel in Europa: STOXX 50 schliesst im Minus